Guardant Health, Inc. (GH)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

42.04

-0.22

(-0.52%)

At close: 04:00PM EDT

42.04

0.00

(0.00%)

After hours:

06:20PM EDT

Advertisement

A
What's behind the big rise today?
J
Guardant Health Completes Purchase of Guardant Health AMEA Joint Venture which I believe is a dilution of the balance sheet. At these times this is not a prudent move.
S
Thanks, I'll check them out.Thanks for the tip!Thanks for the update!
J
Has the FDA approved this test? Has the test been accepted by any insurance networks?
S
When does the ECLIPSE test report out?
F
It seems investors lost interests in GH
J
Massively undervalued. $3bn market cap with $1.6bn cash. Revenues of $460m-$470m expected this year. Clinical volumes up 47%. Shield LDT now launched.
E
This stock has suffered a sharp PPS decline to a level that it now looks to be a very good bargain basement play. It has great technology and an enormous TAM, and the EPIC deal is going to speed it's sales growth significantly, as it expands its product offerings. It is the clear leader in "liquid biopsy" and the many ways this technology can be used is quite promising for huge profits over time as sales growth is set to explode, IMO. Please don't listen to the short sellers that have latched onto this stock as it suffered a price decline in a difficult market environment. If you buy and hold till the market swings into a more positive mood, it will be recognized for the growth and profit potential that it has. Test results coming by the end of the year should help PPS from here. With its current $3 B MC and strong sales growth, it should be expected to provide a great investment for those that buy and patiently hold. GLTY and please do your own research and DD and never base your decisions on posters.
B
This is going to be $3-4 !!
F
Sell a big loss. Just hold onto it
Hope one day it may go up again
Neutral
S
If the ECLIPSE test doesn’t produce outstanding results, this stock is DOA
e
I am not understanding what Doctor would prescribe a test that is not FDA approved? Am I missing something?
F
Ask the noticeably absent @Pauline how this cash printing machine is doing? Certainly not making any cash. Time to revise that target price down closer to $55. Even that would be a stretch.
F
A little rise, a bigger fall. A little less rise, a bigger fall. After 6 months that story is getting old. And to think they are in the market for your health. Right….
K
worse investment ever
F
Hahaha, off 33% in May and trying to outdo itself in June.
J
On the other hand profitability for testing isn't easy :
Illumina (NASDAQ:ILMN) saw its Q1 2022 net income decline ~41% compared to the prior-year period due to a significant operating loss from its GRAIL division, which was acquired in August 2021.
O
EXAS tried marketing a non approved early version of a stool CRC screening test called PreGenPlus in 2007. FDA was not pleased and sent EXAS a letter saying they believed regulatory approval was required for their device. Market responded as you would expect and the stock was punished.
F
It’s a long way reach that $123 target price. Can’t see that happening, regardless of valuation, underselling, overselling, or anything else.
J
Huge mistake from being swept up from the noble goal of predictive diagnostics, while ignoring the company's performance.
The question now is to hold and hope for a buyout, or sell into the bounce.
Unless the find a way to become profitable, the euphoria of last year is gone.